About Us

About our Company

PharmaDiagnostics was founded in 2007 and is based in Brussels. We offer services on our unique technology platform, SoPRano™, to life science researchers engaged in biomolecular interaction analysis and label-free screening and detection of protein-protein interactions.

The SoPRano™ platform is based upon the principle of localised surface plasmon resonance (LSPR), a variant of the well known SPR principle. Unlike all other SPR technology platforms which require a dedicated specialist instrument, the SoPRano™ platform enables label-free screening using only a standard absorbance plate-reader. The technology uses gold nanomaterials in solution, which when conjugated to a specific protein, exhibit changes in optical density upon interaction with a protein ligand. For the first time label-free screening can be used in high throughput and without the burden of investing in and supporting an expensive dedicated instrument.

Our Investors

Pharma Diagnostics has raised more than EUR 5 million (USD 6.3 M) in three rounds of venture funding and EUR 280,000 in grants from IWT (Instituut voor de aanmoediging van innovatie door Wetenschap & Technologie in Vlaanderen), the Flemish innovation agency. The lead investor is Pierre Saelen, an intellectual property consultant and business angel. Other investors include Allegro Investment Fund, a Leuven, Belgium-based venture fund, Capital-E, an Antwerp, Belgium-based venture fund, Vinnof, the Flemish innovation fund, PhD Partnership (a consortium of business angels), and Patrick Englebienne and Anne Van Hoonacker, the original inventors and founders of the company.

Web Design Cornwall